Biologic research is experiencing a transformation brought about by the ability of programmable nucleases to manipulate the genome. In the recently developed CRISPR/ Cas system, short RNA sequences guide the endonuclease Cas9 to any location in the genome, causing a DNA double-strand break (DSB). Repair of DSBs allows the introduction of targeted genetic manipulations with high precision. Cas9-mediated gene editing is simple, scalable, and rapid, and it can be applied to virtually any organism. Here, we summarize the development of modern gene editing techniques and the biology of DSB repair on which these techniques are based. We discuss technical points in applying this technology and review its use in model organisms. Finally, we describe prospects for the use of gene editing to treat human genetic diseases. This technology offers tremendous promise for equipping the nephrology research community to better model and ultimately, treat kidney diseases.
Gene editing can be defined as the process of permanently altering cellular DNA sequences to introduce a desired mutation. Although manipulating DNA has formed a foundation for modern biomedical research efforts for the last 40 years, remarkable new approaches are revolutionizing this process. Mutations can now be introduced into the genomic DNA of cells from virtually any species. These advances have been made possible using custom nucleases, proteins that can now be targeted to specific sites in the genome, where they can correct mutations, introduce new DNA, activate or suppress transcription, and perform other functions. Increasingly, these exciting and powerful approaches are affecting clinical applications in addition to basic research.
Early approaches to site-specific genome modification relied on homologous recombination, a powerful method to introduce a sequence of interest to a specific DNA locus. This discovery was the subject of a Nobel Prize to Mario R. Capecchi, Sir Martin J. Evans, and Oliver Smithies in 2007, but it is also a relatively inefficient and time-consuming technique requiring considerable operator experience. 1, 2 Research into cellular repair mechanisms for DNA double-strand breaks (DSBs) underpins newer approaches to gene editing. Cells have two primary repair pathways: homology-directed repair (HDR) and nonhomologous end joining (NHEJ) (Figure 1 ). We will discuss a third pathway, microhomologymediated end joining (MMEJ), below. HDR uses homology regions between the exposed ends of a DSB and a donor DNA template to repair the cut region. By contrast, in the NHEJ pathway, the broken ends of the DSB are ligated back together. Because this process involves processing of the broken ends to generate compatible ends, the repair often results in small deletions or insertions. 3 The important concept is that, if one can introduce a DSB at a desired locus, then either mode of repair might come into play, leading to a permanent genetic alteration. As a consequence, investigators have searched intensively for methods of inducing DSBs at a precise location.
The early forms of customized nucleases, such as Zinc Finger Nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), were engineered to bind specific DNA sequences using knowledge of specific DNA recognition mechanisms shared by transcription factors. For example, zinc finger (ZF) domains in eukaryotic transcription factors 4, 5 and transcription activatorlike effectors (TALEs) from Xanthomonas bacteria 6-8 recognize specific DNA sequences. By designing a cDNA to encode tandem repeats of these ZF or TALE modules, synthetic proteins result that target a specific DNA sequence up to 18 bp. 9 By fusing the synthetic ZF or TALE with a nuclease, such as Fokl (a nonspecific restriction endonuclease from Flavobacterium okeanokoites), a DSB is induced at the precise location where the ZF or TALE binds. 10 Both of these approaches advanced the field considerably, but they also suffer from major limitations. Assembling tandem repeats of ZFs and TALEs is laborious because of the repetitive sequences, and a single ZF nuclease may not be active; therefore, researchers often order several to produce one active nuclease. 11 Although TALEs are highly independent of neighboring repeats and not as labor intensive to create, binding sites are limited to sequences that start with a T base, 12 and they also require considerable validation.
In contrast to ZFNs and TALENs, the recent clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated endonuclease (Cas) system is considerably simpler to design and use.
It is also cheaper. A single ZF costs about $5000, and a single TALEN might be $500 if a laboratory constructs it on their own. By contrast, a single CRISPR/Cas experiment costs only the $30 required to synthesize short oligonucleotides. The CRISPR/Cas technology is based on the bacterial adaptive immunity system entitled CRISPR. This system provides adaptive immunity against foreign DNAs, such as viruses and plasmids. The type 2 CRISPR system first identifies foreign DNA, and then, the Cas cuts this foreign DNA into small pieces. These are subsequently incorporated into a CRISPR locus within the bacterial genome. These loci are then transcribed to generate small RNAs, which will eventually guide the Cas endonuclease to that same foreign DNA sequence, on the basis of RNA-DNA sequence complementarity. [13] [14] [15] A distinguishing feature of the CRISPR-Cas defense is that it uses RNA-DNA binding to guide the nuclease to specific genetic sequences rather than protein-DNA binding as with ZFNs and TALENs.
DEVELOPMENT OF THE CRISPR/ CAS SYSTEM
The CRISPR/Cas system offers a dramatically simpler target design approach than either ZFN or TALEN methods. In fact, CRISPR technology has become so flexible, powerful, and easy to use that Science magazine named it the 2015 Breakthrough of the Year. 16 Of the three types of CRISPR systems identified to date, type 2 has been adapted for development because of its simplicity. 17, 18 In type 2 systems, the CRISPR array is transcribed as preclustered, regularly interspaced, short palindromic repeats RNA (precrRNA), which hybridizes with target-independent transactivating clustered, regularly interspaced, short palindromic repeats RNAs (tracrRNAs) to form a complex with Cas9 proteins. During crRNA maturation, each crRNA-tracrRNACas9 complex is released as an active DNA nuclease. The complex first scans DNA for a protospacer motif (PAM) and binds to sequences exhibiting complementarity to the 20-nucleotide cRNA that are immediately followed by the PAM. 19 The canonical PAM for the most commonly used Streptococcus pyogenes Cas9 is 59-NGG-39, where N can be any nucleotide (Figure 1 ). 18 Scientists have simplified the dual tracrRNA-crRNA system by engineering a single guide RNA (sgRNA) that combines tracrRNA-crRNA functions. This leaves a two-component system, in which one can target any DNA sequence simply by introducing the Cas9 nuclease and appropriate sgRNA into target cells. 17 An sgRNA target can be any sequence as long as it is immediately followed by the PAM sequence, which is so common that this is not a practical limitation. There are a variety of online resources available to identify genomic loci with unique sequences to minimize off-target effects (Table 1 ). The sgRNA target sequence is typically synthesized as a partially complementary oligonucleotide and cloned into a plasmid that encodes a cassette for expression of the sgRNA and Cas9. The plasmid may also encode either a fluorescent marker or resistance gene, enabling enrichment of transfected cells. The delivery method varies depending on the cell line: standard transfection methods may be sufficient for easy to transfect cell lines, whereas electroporation or viral delivery can be used for difficult to transfect cell lines. The activity of sgRNAs can be tested by several straightforward methods (Table 2) .
BASIC KNOCKOUT AND KNOCK-IN CRISPR/CAS APPLICATIONS
To knock out a gene, an sgRNA can be designed to bind to the 59 end of the coding region. After a DSB is introduced and repaired through NHEJ, small deletions or insertions will be created, many causing frameshift mutations that result in nonsense-mediated decay. Alternatively, two sgRNAs can be designed at the 59 and 39 ends of the gene to delete the whole genic region (Figure 2A ). In the former approach, it may be time consuming to screen clones, because DNA from each clone has to be individually sequenced to identify frameshift mutations. In the latter approach, screening can be carried out efficiently by PCR. For example, Figure 2 depicts one such strategy, in which two sgRNAs flank a long genic region, and the screening primers are located upstream and downstream of the sgRNAs. With a 1-minute extension PCR, deleted alleles yield PCR products, whereas the wild-type allele is too large to amplify ( Figure 2 ).
To introduce specific genetic alterations, such as reporters and diseasespecific mutations, knock-in strategies may be used. In this case, an additional DNA template must be provided along with the plasmid-encoding Cas9 and the sgRNA. This additional DNA must have two homology arms and the desired new DNA sequence in between them. Insertion of small epitope tags can be accomplished with single-stranded oligonucleotides using homology arms of about 60 nucleotides. Insertion of a larger sequence, such as green fluorescent protein, requires a plasmid donor with longer homology arms of around 0.8 kb. When this donor DNA with homology arms adjacent to the cut site is present, the HDR pathway may be Online program that determines the ratio of mutated alleles in a background of wild-type alleles; chromatogram from sequencing of the region around the sgRNA site is uploaded, and the algorithm calculates the ratio of mutated alleles Deep sequencing
The most sensitive method: it provides not only efficiency of sgRNA edits but also, detailed sequence-based information on the kinds of mutations that each gRNA can generate triggered, and the novel sequences located in between the homology arms will be incorporated. Figure 3 shows successful introduction of a 2.6-kb insert using 0.8-to 1-kb homology arms. A donor-specific primer and a primer that anneals outside the region spanned by the homology arms should be used to screen clones with knock-in alleles. Clones with the inserted alleles should give PCR bands, whereas wildtype alleles do not ( Figure 3B ). It is best practice to design sgRNAs and donor homology arms in such a manner that the homology arm sequences do not contain the full sgRNA target sequences to ensure that the plasmid donor and repaired locus will not be subject to mutagenic NHEJ outcomes. This can be accomplished by mutating the PAM sequence of the donor plasmid.
NEW APPLICATIONS OF CRISPR USING MODIFIED CAS9
Although the CRISPR/Cas9 system produces DSBs efficiently at target sites, it can also cause off-target mutations at unintended sites. 20 This is because sgRNAs can tolerate mismatched nucleotides and even noncanonical PAMs. Recent developments, however, have significantly improved targeting specificity. One solution involves a nickase version of Cas9 containing a D10A or N863A mutation to inactivate one of two conserved nuclease domains. 21, 22 These nickase mutants use two sgRNAs on opposite strands to make paired singlestrand breaks. Off-target nicks caused by single nickases are less mutagenic than DSBs, because nicks are repaired with high fidelity. 23 The newest addition is enhanced specificity SpCas9 nucleases, which contains triple mutations to neutralize positive charges in the nontarget strand groove, weakening off-target strand binding. SpCas9 is the simplest solution available and outperforms another recent strategy-the truncated sgRNA strategy, which uses sgRNAs shortened by two or three nucleotides to increase sensitivity to mismatches. 24, 25 CRISPR/Cas9 can also be used to recruit effector domains to turn gene transcription off or on (CRISPRi or CRISPRa). Catalytically dead (dCas9) variants, which lack nuclease activity but retain DNA binding capacity, can repress transcription sterically, either by blocking transcription initiation or elongation, when the sgRNA directs dCas9 binding to a promoter or exon. Transcriptional repression (CRISPRi) can also be achieved by fusing dCas9 to a transcriptional repressor domain, such as Krüppel-associated box repressor, and targeting the sgRNA near a transcriptional start site. 26 Activation of target gene transcription (CRISPRa) is also readily accomplished using dCas9. Fusion of an artificial repeat of the VP64 transcriptional activation domain to dCas9 is sufficient to recruit RNA polymerase and initiate transcription at a site determined by dCas9 binding (for example, near a transcriptional start site). 27 This system has recently been improved by fusing several different transcriptional activation domains to dCas9 in tandem. A tripartite construct consisting of the activation domains VP64, p65, and Rta, when fused to dCas9, showed 22-to 320-fold greater activation of endogenous target genes. This dCas9-VP64, p65, and Rta approach also allowed multiplexed activation of up to four genes in the same cell simply through introduction of a collection of guide RNAs targeting those four genes. 28 Finally, dCas9 fused to the catalytic domain of the human acetyltransferase p300 has been reported to accomplish gene-specific epigenome editing. The fusion protein catalyzes histone H3 lysine 27 acetylation around genomic sites targeted by sgRNAs. 29 CRISPR/Cas technology has also been used successfully for large-scale, high-throughput functional screening. For example, by using a lentiviral knockout sgRNA library, a group has identified genes essential for the intoxication of cells by anthrax and diphtheria toxins. 30 Their method involved lentiviral infection of human cultured cells with the sgRNA library to establish library cell lines followed by toxin screening. Surviving cells were then analyzed for their individual sgRNA sequence by deep sequencing, thereby identifying the gene knockout that protected the cell from death by either anthrax or diphtheria.
GENOME ENGINEERING IN MODEL ORGANISMS
CRISPR/Cas9 technology can be readily applied to genome modification in model organisms. Genetically modified mice, for example, are used routinely for analysis of gene function, but generating mouse lines with one or multiple targeted mutations remains expensive and time consuming. The fastest timeline for creating a mouse knockout by standard homologous recombination is about 1 year, and this does not include time required to construct the targeting plasmid. With a CRISPR approach, injection of an sgRNA and Cas9 mRNA or protein into the one-cell embryo creates germline knockout mice in one generation-4 weeks. 31 Moreover, multiple genes can be targeted at once, which is impossible using standard approaches. 32 One-step generation of mouse knockins is also possible, but it is less efficient than creating knockouts. Insertion of small epitope tags can be accomplished by coinjecting an sgRNA, Cas9, and single-stranded oligonucleotide containing the epitope tag and homology arms of about 60 nucleotides. Larger insertions, which require plasmid donors with longer homology arms as described in the previous section, are considerably more challenging to accomplish in a onestep procedure, despite early reports to the contrary. 33 Some investigators have resorted to creating the knock-ins in mouse embryonic stem cells using CRISPR/Cas9 followed by traditional blastocyst injection.
Although gene editing with CRISPR/ Cas9 has been described in myriad other model organisms, including rat, zebrafish, frog, monkey, mosquito, pig, plants, and more, there still remains room to improve gene knock-in efficiency and applicability to organisms with a low HDR frequency. An intriguing recent development, called CRISPR/Cas9 precise integration into target chromosome, takes advantage of a separate DNA repair mechanism called MMEJ to facilitate knock-in. In contrast to the conventional HDR, the MMEJ process requires only short homologous sequences of 5-25 bp. This method features a donor plasmid with short homology arms, and the whole template region is flanked by sgRNA target sites. Therefore, Cas9 generates DSBs in both the genomic DNA and the donor vector, exposing the microhomology sequences that are then used for MMEJ-mediated knock-in of the insert. 34 The precise integration into target chromosome system has been reported to have about 2.5-fold higher efficiency than HDR-mediated knock-ins in cultured cells and has been successfully used in silkworm, zebrafish, and frog. It certainly seems to be a promising technique that needs to be tested in mouse embryos. 35 Additional studies into MMEJ repair mechanisms might improve the methodology further to enable precise and efficient knock-in of large insertions in wholeanimal applications.
Recent reports also document the first successful application of gene editing approaches to the study of kidney disease. Freedman et al. 36 recently reported protocols for the directed differentiation of human pluripotent stem cells (hPSCs) to kidney organoids. Using CRISPR, they knocked out the podocalyxin gene in hPSC. 36 Podocalyxin regulates tight junctions and is expressed in podocytes in mature kidney. After differentiation of wild-type or podocalyxin knockout hPSC to kidney organoids, Freedman et al. 36 reported disappearance of protein tracks of the other podocyte proteins synaptopodin and ZO-1 along with a decrease in the gap width between podocyte-like cells. 36 This proof of principle experiment establishes a novel platform for investigation of kidney genes in hPSCs.
Freedman et al. 36 also generated biallelic loss of function mutations in the polycystic kidney disease 1 (PKD1) and PKD2 genes that are responsible for development of human PKD. After differentiation of these lines and wild-type cells into kidney organoids followed by extended culture, Freedman et al. 36 observed large cyst-like structures apparently emanating from the tubular compartment in organoids. Although these were uncommon at 6% of organoids, this seems to be a highly promising new approach to model cystogenesis in PKD in vitro.
GENE THERAPY PROTOCOLS USING GENOME EDITING TECHNOLOGIES
One of the fastest growing applications of CRISPR/Cas9 approaches is in gene therapy to cure disease. Sickle cell anemia, for example, is caused by a singlenucleotide mutation in the b-globin gene, which encodes a protein subunit of hemoglobin (Hb) found in red blood cells. The mutation does not alter the ability of Hb to carry oxygen, but under hypoxic conditions, it does promote polymerization of intracellular Hb molecules, which in turn, reduces elasticity of the red blood cell and causes shape change called sickling. The now rigid blood cells block small capillaries, causing occlusion and ischemia. 37 One strategy to cure sickle cell anemia is to activate expression of fetal Hb, HbF, which does not require the b-globin subunit and therefore, does not cause sickling. HbF expression is normally downregulated after 6 weeks of age by a transcriptional repressor encoded by the BCL11A gene. 38 A group from the Dana Farber Cancer Institute used a CRISPR/ Cas9 to perform saturation mutagenesis on the human enhancer (a noncoding element) that regulates BCL11A expression. The group identified sgRNAs that caused complete knockout of BCL11A, with subsequent upregulation of HbF expression. 39 This important work provides a framework for therapeutic gene editing in hematopoietic stem cells to restore HbF expression and ameliorate the sickle cell phenotype. The particular enhancer targeted is specific to erythroid elements, thus preserving BCL11A expression in nonerythroid tissues and reducing side effects.
Another disease that seems to be amenable to CRISPR-based gene therapy is Duchenne muscular dystrophy (DMD). This muscle disease mainly affects boys who develop progressive skeletal muscle and heart degeneration and die in their mid-20s. DMD is caused by genetic defects in the gene dystrophin, a component of the muscle cell cytoskeleton. It has been known for some time that manipulations causing the transcriptional machinery to skip the exon containing the mutation result in truncated dystrophin protein that still functions adequately enough to reverse the muscle pathology. 40 Three independent groups very recently reported CRISPR strategies to achieve exon skipping in the dystrophin gene, resulting in improved muscle function in mouse models of DMD. [41] [42] [43] These groups (Olson and coworkers, 41 Gersbach and coworkers, 41 and Wagers and coworkers 43 ) all used adenoassociated viruses (AAVs) to deliver the CRISPR/Cas9 components. AAVs are nonintegrating viruses that are safe for human use, and they efficiently transduce skeletal and heart muscle. Investigators designed novel AAVs that encoded the Cas9 endonuclease along with paired sgRNAs that flank the mutated exon. Simple intravenous injection of the custom AAV resulted in efficient excision of the mutant exon, restoring myofiber and cardiomyocyte function. Wagers and coworkers 43 also showed that excision occurred in muscle stem cells, providing hope that this approach may provide a durable cure if adapted to humans.
POTENTIAL APPLICATIONS TO KIDNEY DISEASE
Applications of CRISPR-mediated gene editing to the treatment of kidney disease can be envisioned. For example, the shortage of transplantable organs remains a critical roadblock to the treatment of ESRD. Xenotransplatation of porcine kidneys has been considered a viable solution to this problem, but concerns about transmission of porcine endogenous retroviruses (PERVs) to humans has limited progress in this field. PERVs cannot be eliminated by biosecure breeding, because these elements are encoded within the pig genome. Recently, Church and coworkers 44 used a CRISPR approach to eradicate a gene critical to PERV function at 62 independent sites within the genome of a pig cell line during a single round of CRISPR. This result provides a proof of principle that the same approach could be used to create pig embryos with inactivated PERV sequences and subsequently, cloned pigs with kidneys free from retroviruses.
PKD represents another potential application for therapeutic gene editing. Most patients develop kidney failure from small mutations in either the PKD1 or PKD2 gene. These types of mutations are amenable to repair by the HDR approach and would only require a relatively short oligonucleotide donor template. Two possible therapeutic approaches might be possible. On the one hand, fibroblasts from an affected patient could be isolated and induced to become pluripotent cells (a standard protocol now). The PKD mutation could be corrected by CRISPR at this point, and the pluripotent cells could then be induced to differentiate into a transplantable kidney, which would have the benefit of being immunologically identical to the patient. 36 Unfortunately, it is not clear when or even if a transplantable kidney can be grown in the laboratory.
An alternative approach would be to deliver Cas9, a gRNA, and the donor template DNA directly to kidney tubular epithelia in patients affected with PKD and correct the gene defect in all of the nephrons of that patient. Here, the major limitation is that there is no clear method to deliver this DNA to the kidney. The AAV approach seems to be the most promising and is already in clinical trials in other organs; however, there is no evidence of any AAV serotype capable of infecting kidney epithelia.
ETHICAL CONSIDERATIONS
The ability to edit the genome with relative ease has led to an intense debate about whether and how this technology might be used to modify the genomes of human embryos. Although in utero or preimplantation genetic screening-for Down syndrome, for example-has existed for years, CRISPR/Cas9 could be used to make changes that are inherited, crossing what some consider an ethical boundary. Some scientists have argued that germline genome editing should be banned because of unpredictable effects on future generations, the impossibility of informed consent, and the possible use of gene editing for nontherapeutic purposes (appearance, for example). 45 Others argue that such a ban would reflect a lack of imagination and lack of faith in society to properly regulate a field with enormous potential benefit to patients suffering from incurable disease. 46 As a result of these concerns, a group of 18 prominent leaders in the field met in 2015 in Napa, California to initiate a discussion on the scientific, medical, legal, and ethical implications of CRISPR/Cas9 gene editing. The group called for a moratorium on the clinical use of germline gene editing until a diverse group of citizens and stakeholders examines the technology and evaluates its risks and potential benefits. 47 
CONCLUSIONS
Over just a few years, the scientific community has witnessed the development of a remarkably powerful, flexible, and exciting new tool for studying and manipulating gene function. We have highlighted the development of gene editing and focused on CRISPR/Cas9-based approaches, currently the most flexible gene manipulation available. These technologies offer the rapid, inexpensive, and efficient targeting of one or multiple genes and are easily accessible for any laboratory environment. These approaches offer powerful new tools to those studying kidney disease and are sure to play an increasingly important role in both kidney investigation and therapeutics in the future.
